SOUTH SAN FRANCISCO, Calif., May 8, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced that the company will present at the Credit Suisse Antibody Conference, to be held in New York City on May 10, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics. (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO) Company Presentation:When: Friday, May 10, 2013, 10:30AM Eastern TimeWhere: One Madison Avenue at 24 th Street, New York, NYAbout KaloBios KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com. Contact:Jeffrey H. CooperChief Financial OfficerKaloBios Pharmaceuticals, Inc.(650) 243-3146 firstname.lastname@example.orgMedia Contact:Joan E. KureczkaKureczka/Martin Associates Tel: (415) 821-2413Mobile: (415) 690-0210 Joan@Kureczka-Martin.com SOURCE KaloBios Pharmaceuticals, Inc.